Logo

American Heart Association

  8
  0


Final ID: WP49

Diagnostic performance of plasma pTau217 for the detection of Cognitive Impairment in a Vascular Disease-Enriched Population

Abstract Body: Cerebral small vessel disease, particularly characterized by white matter hyperintensities (WMHs), is a prominent contributor to cognitive impairment. The concurrent role of Alzheimer's disease (AD) pathology, as measured by hyperphosphorylated tau species (pTau), in vascular cognitive impairment remains unclear. While plasma pTau217 is an established biomarker for AD, its relevance in vascular disease-enriched populations has not been extensively studied. This study investigates plasma pTau217 as a biomarker for distinguishing cognitive impairment and dementia in a cohort de-enriched for AD but enriched for vascular disease, focusing on its relationship with cognitive status and Fazekas scores. A cohort of 72 participants (mean age: 70.4, SD 7.9, 58% female) from the MarkVCID Consortium study were selected with 75% having a Fazekas score ≥ 2. pTau217 levels were quantified using the Meso Scale Discovery S Plex assay. Individuals were classified based on their cognitive status into cognitively normal, mild cognitive impairment (MCI), or dementia. Receiver operating characteristic (ROC) curve analysis was performed to assess the ability of pTau217 to distinguish between these groups. Linear regression models were used to examine the association between pTau217 levels and Clinical Dementia Rating (CDR) global scores. Plasma pTau217 levels were found to be elevated in individuals with MCI and dementia. The ROC curve analysis showed pTau217 could distinguish between patients with MCI (AUC: 0.74) and dementia (AUC: 0.72), suggesting moderate diagnostic accuracy in this vascular disease-enriched cohort. No significant relationship was observed between pTau217 levels and Fazekas scores. Regression analysis revealed plasma pTau217 levels were significantly associated with CDR global scores (β=0.337; p=0.0007), a correlation that remained significant after adjusting for sex, age, and education, underscoring pTau217 as an independent predictor of cognitive decline. Additionally, 75% of participants with an AD diagnosis (6/8) had pTau217 levels >10 pg/mL (consistent with prior studies) ranging from 12.2 to 35.3 pg/mL. In conclusion, for this cohort enriched for vascular disease and de-enriched for AD, plasma pTau217 exhibited accuracy in distinguishing patients with MCI and dementia, independent of Fazekas scores. These findings support the utility of plasma pTau217 as a biomarker for cognitive impairment, even in populations with a significant vascular pathology.
  • Gunda, Rashmika  ( UCLA , Los Angeles , California , United States )
  • Chatterjee, Roopsha  ( Western University of Health Sciences , Pomona , California , United States )
  • Windon, Charles  ( University of California, San Francisco , San Fransisco , California , United States )
  • Hinman, Jason  ( UCLA MEDICAL CENTER , Los Angeles , California , United States )
  • Author Disclosures:
    Rashmika Gunda: DO NOT have relevant financial relationships | Roopsha Chatterjee: DO NOT have relevant financial relationships | Charles Windon: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Onviv (honorarium):Past (completed) ; Speaker:Urban Strategies (honorarium):Past (completed) ; Other (please indicate in the box next to the company name):AAN (honorarium):Past (completed) ; Research Funding (PI or named investigator):Alzheimer's Assocation:Active (exists now) ; Research Funding (PI or named investigator):NIH:Past (completed) ; Other (please indicate in the box next to the company name):Kinetix Group (honorarium):Past (completed) ; Other (please indicate in the box next to the company name):LCN (honorarium):Past (completed) | Jason Hinman: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Brain Health Posters I

Wednesday, 02/05/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)